Lauren Hermann, DO
Obstetrics & Gynecology · San Marcos, TXNPI 1568783900
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 47.2% of the total. 2025 is the largest year on record at $538, 4.1 times the $132 reported in 2019.
Across 139 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Exeltis, USA Inc.$138
- Mayne Pharma Commercial LLC$137
- Organon$99
- Therapeuticsmd, Inc.$99
- Biogen$94
- plus $666 from 16 others
What the payments were for
- Food & beverage$2,337100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,104 |
| Exeltis, USA Inc. | 8 | $138 |
| Mayne Pharma Commercial LLC | 7 | $137 |
| Organon | 8 | $99 |
| Therapeuticsmd, Inc. | 7 | $99 |
| Biogen | 5 | $94 |
| Agile Therapeutics, Inc. | 5 | $85 |
| Sumitomo Pharma America, Inc. | 4 | $79 |
| Coopersurgical, Inc. | 4 | $73 |
| Pfizer | 3 | $63 |
| Millicent US Inc | 3 | $59 |
| Lupin Inc. | 4 | $55 |
| Astellas Pharma US Inc | 3 | $48 |
| Shield Therapeutics Inc | 3 | $44 |
| Avion Pharmaceuticals | 2 | $42 |
| Myovant Sciences Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Axonics, Inc. | 1 | $20 |
| Urovant Sciences Inc | 1 | $16 |
| Mylan Pharmaceuticals Inc. | 1 | $14 |
| Aspira Women's Health Inc | 1 | $13 |
| Mission Pharmacal Company | 1 | $12 |
How this compares
$2,337 in reported general payments places this provider in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 122 | $4,148 |
| YuvafemEstradiol | 19 | $2,177 |
| Clobetasol Propionate | 26 | $1,695 |
| ProgesteroneProgesterone, Micronized | 17 | $404 |
| Fluconazole | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in San Marcos
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Dale StovallDallas$590K
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
- Catherine HansenWebster$357K
- Lisa JukesBee Cave$270K
- Susan CrockettLive Oak$269K
- Henry Garza IiiSan Antonio$258K
- Rene LunaMcAllen$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.